Hallux Abducto ValgusPhase 2DYSTANCENCT03569098
Dysport in Hallux Abducto Valgus (HAV) Phase IIa
A Phase 2 study testing Botulinum toxin type A in people with Hallux Abducto Valgus, run by Ipsen at 29 sites in United States.
Trial summary
The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hallux Abducto Valgus
- What is being tested?
- Botulinum toxin type A
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 186 participants
- Where
- 29 sitesUnited States
- Study dates
- 19 Jun 2018to 22 May 2020
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical diagnosis of HAV
- Painful HAV in the study foot at Baseline
Who cannot join
- Flat or square metatarsal head, metatarsus primus elevates, or severe cavus/planus in the study foot
- Other podiatric or orthopedic condition which would interfere with the evaluation of pain and/or function
- Medical history or clinical evidence of any vascular disease and/or diabetic condition
Trial locations and contacts
29 sites in 1 country.
29 sites in 1 country
United States29 sites
Podiatry 1st
Belleville, Illinois, 62226
Foot and Ankle Center
Bryn Mawr, Pennsylvania, 19010
Center for Clinical Research Inc.
Castro Valley, California, 94546
Weil Foot & Ankle Institute
Des Plaines, Illinois, 60016
Limb Preservation Platform, Inc.
Fresno, California, 93710
Harrisburg Foot and Ankle Center, INC
Harrisburg, Pennsylvania, 17112
Harrisonburg Foot and Ankle Clinic
Harrisonburg, Virginia, 22801
NEA Baptist Clinic
Jonesboro, Arkansas, 72401
Applied Research Center of Arkansas, Inc
Little Rock, Arkansas, 72212
Southwestern Academic Limb Salvage Alliance
Los Angeles, California, 90033
Foot and Ankle Clinic
Los Angeles, California, 90057
Futuro Clinical Trials, LLC
McAllen, Texas, 78501
LCC Medical Research Institute
Miami, Florida, 33126
Rosalind Franklin Clinic
North Chicago, Illinois, 60064
Medical Research International
Oklahoma City, Oklahoma, 73109
Conquest Research
Orlando, Florida, 32822
The Chesapeake Research Group
Pasadena, Maryland, 21122
Martinsville Research Institute, Inc.
Salem, West Virginia, 24153
Summit Foot & Ankle
Salt Lake City, Utah, 84117
Bio X Cell Research
San Antonio, Texas, 78229
University Foot and Ankle Institute
Santa Monica, California, 90403
Doctors Research Network
South Miami, Florida, 33301
Foot and Ankle Center of Illinois
Springfield, Illinois, 62704
Dr. Allen M. Jacobs and Associates
St Louis, Missouri, 63117
1Foot 2Foot Centre for Foot and Ankle Care, PC
Suffolk, Virginia, 23434
Center for Spine and Orthopedics
Thornton, Colorado, 80229
Texas Gulf Coast Medical Group
Webster, Texas, 77598
Clinical Research
West Palm Beach, Florida, 33406
Ankle and Foot Care Centers
Youngstown, Ohio, 22801
About this study
Official title: A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus
The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.
- Conditions
- Hallux Abducto Valgus
- Being tested
- Botulinum toxin type A, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Botulinum toxin type ABiological
Also called AbobotulinumtoxinA (Dysport®), Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC)
Investigators will inject the reconstituted solution into foot muscles.
PlaceboDrug
Investigators will inject the reconstituted solution into foot muscles.
| Study group | Role | What they receive |
|---|---|---|
| Dysport Dose 1 | Experimental | Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks. Receives: Biological: Botulinum toxin type A |
| Dysport Dose 2 | Experimental | Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks. Receives: Biological: Botulinum toxin type A |
| Placebo | Placebo comparator | Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period) Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8
The NPRS is a widely used and validated unidimensional measure of pain intensity in adults. Participants were asked to rate the intensity of their foot pain during physical activity (example, walking, standing or running) based on an 11-point scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst possible pain". Higher scores indicate a worse outcome. Daily pain intensities were recorded by the participant using an electronic diary (eDiary) for 7 consecutive days prior to each study visit. Baseline was defined as the daily NPRS score averaged over the 7 consecutive days prior to the Baseline visit (Day 1).
Measured: Baseline and Week 8 in the double-blind treatment period
Secondary outcomes (13)
LS Mean Change From Baseline in the Daily NPRS Score at Weeks 4 and 12
The NPRS is a widely used and validated unidimensional measure of pain intensity in adults. Participants were asked to rate the intensity of their foot pain during physical activity (example, walking, standing or running) based on an 11-point scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst possible pain". Higher scores indicate a worse outcome. Daily pain intensities were recorded by the participant using an eDiary for 7 consecutive days prior to each study visit. Baseline was defined as the daily NPRS score averaged over the 7 consecutive days prior to the Baseline visit (Day 1).
Measured: Baseline and Weeks 4 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily Modified Foot Function Index (mFFI) Disability Subscale Score at Weeks 4, 8 and 12
The foot function index (FFI) was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into 3 subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI disability subscale is rated using numeric rating scale ranging from 0 to 10, where 0 represents "no difficulty" and 10 represents "so difficult unable to do". For each item, the participant was asked to record the number value which best corresponded to effect of the foot complaints. To obtain a subscale score, the item scores for a given subscale (i.e., pain, disability or activity limitation subscales) were totaled and divided by maximum total possible and then multiplied by 100. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily mFFI Pain Subscale Score at Weeks 4, 8 and 12
The FFI was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of the FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into 3 subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI pain subscale is rated using numeric rating scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst pain imaginable". For each item, the participant was asked to record the number value which best corresponded to the effect of the foot complaints. To obtain a subscale score, the item scores for a given subscale (i.e., pain, disability or activity limitation subscales) were totaled and divided by the maximum total possible and then multiplied by 100. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily mFFI Total Score at Weeks 4, 8 and 12
The FFI was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of the FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into three subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI items are rated using numeric rating scales ranging from 0 to 10, where 0 represents "no pain/no difficulty/none of the time" and 10 represents "worst pain imaginable/so difficult unable to do/all of the time" for pain, disability and activity limitation subscales, respectively. For each item, the participant was asked to record the number value which best corresponded to the effect of the foot complaints. To obtain a total score, the scores of all 3 subscales were totaled and divided by 3. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily mFFI Activity Limitation Subscale Score at Weeks 4, 8 and 12
The FFI was developed to assess foot-related pain, disability and activity limitations and later revised to include foot-related health and quality of life. A modified version of the FFI specific to this study was used. The mFFI consists of a total of 21 items grouped into 3 subscales: pain (7 questions), disability (9 questions) and activity limitation (5 questions). The mFFI activity limitation subscale is rated using numeric rating scale ranging from 0 to 10, where 0 represents "none of the time" and 10 represents "all of the time". For each item, the participant was asked to record the number value which best corresponded to the effect of the foot complaints. To obtain a subscale score, the item scores for a given subscale (i.e., pain, disability or activity limitation subscales) were totaled and divided by the maximum total possible and then multiplied by 100. Each subscale score, as well as the total score, ranged from 0 to 100. Higher scores indicate a worse outcome.
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in HV Angle at Weeks 4, 8 and 12
The HV angle was measured directly on weight-bearing anteriorposterior radiographs, in which the X-ray beam was angled 15° towards the heel centered on the second tarsometatarsal joint with a source to image-receptor distance of 100 centimeters (cm).
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in Intermetatarsal Angle at Weeks 4, 8 and 12
The intermetatarsal angle was measured directly on weight-bearing anteriorposterior radiographs, in which the X-ray beam was angled 15° towards the heel centered on the second tarsometatarsal joint with a source to image-receptor distance of 100 cm.
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
Median Time to Retreatment
Time to retreatment was calculated as ([Date of retreatment - previous injection date] + 1) / 7 (week). Time to retreatment was calculated for each cycle and the data presented here for the double-blind treatment period.
Measured: Up to 24 weeks in the double-blind treatment period
LS Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) of Foot Pain Score at Weeks 4, 8 and 12
An assessment of PGI-S of foot pain was conducted by the participant using a 4-point Likert scale ranging from 0= no pain to 3= severe pain. Higher scores indicate a worse outcome. The PGI-S was assessed by the participant by answering the following question: "How severe was your foot pain while performing physical activities (example, standing, walking or running) over the past week?" (0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain).
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in PGI-S of Disability Score at Weeks 4, 8 and 12
An assessment of PGI-S of disability was conducted by the participant using a 4-point Likert scale ranging from 0= no disability to 3= severe disability. Higher scores indicate a worse outcome. The PGI-S was assessed by the participant by answering the following question: "How severe was your disability while performing physical activities (example, standing, walking or running) over the past week?" (0=no disability; 1=mild disability; 2=moderate disability; 3=severe disability).
Measured: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Patient Global Impression of Improvement (PGI-I) of Foot Pain Score at Weeks 4, 8 and 12
An assessment of PGI-I of foot pain was conducted by the participant using a 7-point Likert scale ranging from -3= very much worse to +3= very much improved. Higher scores indicate a better outcome. The PGI-I was assessed by the participant answering the following question: "Compared to your foot pain prior to the study treatment initiation, your foot pain while performing physical activities (example, standing, walking or running) now is: +3=very much improved; +2=much improved; +1=minimally improved; 0=no change; -1=minimally worse; -2=much worse; -3=very much worse".
Measured: Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean PGI-I of Disability Score at Weeks 4, 8 and 12
An assessment of PGI-I of the participant's disability was conducted by the participant using a 7-point Likert scale ranging from -3= very much worse to +3= very much improved. Higher scores indicate a better outcome. The PGI-I was assessed by the participant answering the following question: "Compared to your disability prior to the study treatment initiation, your disability while performing physical activities (example, standing, walking or running) now is: +3=very much improved; +2=much improved; +1=minimally improved; 0=no change; -1=minimally worse; -2=much worse; -3=very much worse".
Measured: Weeks 4, 8 and 12 in the double-blind treatment period
Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score at Weeks 8 and 12
The SF-36 is a 36-item questionnaire which measures the extent to which physical health impacts an individual's functional ability and perceived wellbeing in mental, social, and physical aspects of life. The SF-36 has 8 subscales: physical function, role physical, bodily pain, global health, vitality, social function, role emotional and mental health. Each scale ranges from 0-100, where 0= lowest level of health and 100= highest level of health. Scores on these subscales can be aggregated into the physical component summary (physical function, role physical, bodily pain and global health) and mental component summary (mental health, vitality, social function and role emotional). Physical component summary score ranges from 0.65 to 80.73 and mental component summary score ranges from -8.81 to 81.65, where low score indicates lowest level of health and high score indicates highest level of health. Positive change from Baseline indicates an improvement in quality of life.
Measured: Baseline and Weeks 8 and 12 in the double-blind treatment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2018
- Study start19 Jun 2018
- Primary completion17 Dec 2019
- Study completion22 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Hallux Abducto ValgusStudies of the same condition, open and under way.
- More trials run by IpsenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 186 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ipsen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ipsen Medical Director, Study director, Ipsen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03569098
- Sponsor's protocol ID
- D-FR-52120-237
- Acronym
- DYSTANCE
- Status last verified
- Jul 2021
- First submitted
- 14 Jun 2018
- Last updated
- 2 Jul 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus
- ClinicalTrials.gov ID
- NCT03569098
- Acronym / sponsor ID
- DYSTANCE / D-FR-52120-237
- Conditions
- Hallux Abducto Valgus
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 186 participants (actual)
- Lead sponsor
- IpsenIndustry (pharma, biotech, devices)
- Study start
- 19 Jun 2018 (actual)
- Primary completion
- 17 Dec 2019 (actual)
- Study completion
- 22 May 2020 (actual)
- First posted
- 26 Jun 2018 (actual)
- Results
- Posted 2 Jul 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Dysport Dose 1 | Experimental | Biological: Botulinum toxin type AIntramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks. |
| Dysport Dose 2 | Experimental | Biological: Botulinum toxin type AIntramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks. |
| Placebo | Placebo comparator | Drug: PlaceboIntramuscular injection of Placebo on day 1 of cycle 1 (double-blind period) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Clinical diagnosis of HAV
- Painful HAV in the study foot at Baseline
Key exclusion criteria (3 listed)
- Flat or square metatarsal head, metatarsus primus elevates, or severe cavus/planus in the study foot
- Other podiatric or orthopedic condition which would interfere with the evaluation of pain and/or function
- Medical history or clinical evidence of any vascular disease and/or diabetic condition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Botulinum toxin type AAlso: AbobotulinumtoxinA (Dysport®), Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC)Investigators will inject the reconstituted solution into foot muscles. | Biological | Dysport Dose 1, Dysport Dose 2 |
| PlaceboInvestigators will inject the reconstituted solution into foot muscles. | Drug | Placebo |
Primary outcome
Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8
Time frame: Baseline and Week 8 in the double-blind treatment period
The NPRS is a widely used and validated unidimensional measure of pain intensity in adults. Participants were asked to rate the intensity of their foot pain during physical activity (example, walking, standing or running) based on an 11-point scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst possible pain". Higher scores indicate a worse outcome. Daily pain intensities were recorded by the participant using an electronic diary (eDiary) for 7 consecutive days prior to each study visit. Baseline was defined as the daily NPRS score averaged over the 7 consecutive days prior to the Baseline visit (Day 1).
13 secondary outcomes
LS Mean Change From Baseline in the Daily NPRS Score at Weeks 4 and 12
Time frame: Baseline and Weeks 4 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily Modified Foot Function Index (mFFI) Disability Subscale Score at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily mFFI Pain Subscale Score at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily mFFI Total Score at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in the Daily mFFI Activity Limitation Subscale Score at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in HV Angle at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in Intermetatarsal Angle at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
Median Time to Retreatment
Time frame: Up to 24 weeks in the double-blind treatment period
LS Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) of Foot Pain Score at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Change From Baseline in PGI-S of Disability Score at Weeks 4, 8 and 12
Time frame: Baseline and Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean Patient Global Impression of Improvement (PGI-I) of Foot Pain Score at Weeks 4, 8 and 12
Time frame: Weeks 4, 8 and 12 in the double-blind treatment period
LS Mean PGI-I of Disability Score at Weeks 4, 8 and 12
Time frame: Weeks 4, 8 and 12 in the double-blind treatment period
Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score at Weeks 8 and 12
Time frame: Baseline and Weeks 8 and 12 in the double-blind treatment period
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ipsen Medical Director study director
Ipsen
29 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Botulinum toxin type A in people with Hallux Abducto Valgus, run by Ipsen at 29 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 29 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Jul 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Least Square (LS) Mean Change From Baseline in the Daily Numeric Pain Rating Scale (NPRS) Score at Week 8 (time frame: Baseline and Week 8 in the double-blind treatment period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2021.